2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6325 Patient characteristics and treatment experience with belantamab mafodotin combination therapies for patients with relapsed/refractory multiple myeloma in a global managed access program

Ruben Niesvizky, MD, Anthony James Morton, MD2, Michel Delforge, MD3, Fernando Vieira Pericole, MD, PhD4, Eirini Katodritou, MD, PhD5, Yael C. Cohen, MD6, Elena Zamagni, MD, PhD7, Christian Ramos8, Rajeev Rajagopal, MD, MBBS9, Amalia Domingo González, MD10, Chia-Jen Liu11, Eva Medvedova12, Claire Wardell13, Chris Nikolaidis, MD, PhD, MSc14, John Hartman, PhD15, Brenna O'Neill16, Benga Kazeem17, Clifton C. Mo, MD18
1 Weill Cornell Medical College, New York, New York, United States
2 Icon Cancer Centre, South Brisbane, Australia
3 University of Leuven, Leuven, Belgium
4 Hemocentro UNICAMP, Universidade Estadual de Campinas (UNICAMP), São Paulo, Brazil
5 Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
6 Tel Aviv Sourasky (Ichilov) Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
7 University of Bologna, Bologna, Italy
8 Hospital General de Mexico, Mexico City, Mexico
9 Middlemore Hospital, Auckland, New Zealand
10 Fundación Jiménez Díaz Hospital, Madrid, Spain
11 Taipei Veterans General Hospital, Tapei, Taiwan
12 Oregon Health & Science University, Portland, Oregon, United States
13 GSK, London, United Kingdom
14 GSK, Baar, Zug, Switzerland
15 GSK, Upper Providence, PA, United States
16 GSK, Waltham, Massachusetts, United States
17 GSK, London, United Kingdom
18 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States

Introduction: Patients with multiple myeloma (MM) require multiple therapies over time due to the relapsing nature of the disease. As treatment outcomes worsen with each successive line of therapy, there is a need to deliver the most effective therapies as early as possible during the disease course. B-cell maturation antigen (BCMA)-targeting therapies have transformed treatment of relapsed/refractory MM (RRMM), delivering unprecedented overall survival outcomes vs standard-of-care triplet therapies. Belantamab mafodotin (belamaf) is a BCMA-targeting antibody-drug conjugate that demonstrated robust efficacy for RRMM as part of combination regimens with bortezomib/dexamethasone (BVd; DREAMM-7 trial) and pomalidomide/dexamethasone (BPd; DREAMM-8 trial). Ahead of belamaf regulatory approval in the second-line or later setting in 2025, a global managed access program was initiated to facilitate patient access to BVd/BPd. We report early patient characteristics and dosing patterns in the real world.

Methods: Patients from 19 countries, including the US and EU, who were treated with belamaf through a global managed access program, consented to analysis of data prospectively collected during the program. Patients with ocular comorbidities at baseline were permitted. Data were captured on patient demographics, disease/clinical characteristics, and treatment history. The treatment period with belamaf for this analysis was November 2025 to June 2026.

Results: In total, 955 patients were approved for belamaf combination therapy, of whom 588 (62%) were enrolled with BVd and 367 (38%) with BPd, with 315 (54%) BVd-enrolled pts and 190 (52%) BPd-enrolled pts confirming treatment start at the time of the data cutoff. The median age of patients approved for BVd and BPd was 68 years and 72 years, respectively. Before approval for treatment with BVd or BPd, patients received a median (range) of 2.0 (1–15) prior therapies, with most having between 1–3 prior lines of treatment. At screening, 244 (42%) and 243 (66%) patients receiving BVd or BPd were refractory to anti-CD38 agents, and 278 (47%) and 287 (78%) patients were refractory to lenalidomide, respectively.

At data cutoff, 223/315 (71%) of BVd-treated patients and 132/190 (69%) of BPd-treated patients remained on treatment. Among patients who discontinued treatment (n=92 BVd and n=58 BPd), the most common reasons for discontinuation were disease progression (47% and 38% for BVd and BPd, respectively) or death (26% and 10%), with rates of discontinuations due to AEs being infrequent (3% and 10%). Patients received a median (range) of 3.0 (1–16) doses of BVd and 3.0 (1–12) doses of BPd over a median (range) treatment duration of 105 (21–510) days and 110 (28–469) days, respectively. In both BVd and BPd arms, the majority of patients (92%) started belamaf at 2.5 mg/kg at planned schedules of Q3W (BVd) or Q4W (BPd, with planned reduction to 1.9 mg/kg Q4W from dose 2). Across doses 2–6+, belamaf dose intervals were extended frequently for both BVd (24.4%–55.2%) and BPd (18.9%–40.8%). For BVd, the median time between doses increased from 3.9 weeks during the first 3 months after treatment initiation to 6.9 weeks in the 4–6 months after initiation. For BPd, the median time between doses increased from 4 weeks during the first 3 months after treatment initiation to 7.2 weeks in the 4–6 months after initiation.

Conclusions: These early real-world data support high rates of treatment persistence for BVd and BPd in routine clinical practice, with very low discontinuation rates due to AEs and evidence that a substantial proportion of patients remained on treatment during the early follow-up period of the program. The dose reductions and extended dosing intervals utilized in this global, managed access real-world setting support the effective management of treatment, with continued therapy and ongoing follow-up expected to further characterize longer-term treatment patterns and outcomes.

Ruben Niesvizky, MD: Janssen - Research Funding; Karyopharm therapeutics - Research Funding; BMS - Research Funding; Takeda - Research Funding; GSK - Research Funding; BMS - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Karyopharm therapeutics - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)